Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 28;142(12):1190–1204. doi: 10.1161/CIRCULATIONAHA.120.048191

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 American Heart Association, Inc.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 5. — ACE2-K788R alleviates pulmonary hypertension in ACE2-S680L mice. A, Eight-week-old ACE2-S680D (ACE2-D) and ACE2-S680L (ACE2-L) mice were subjected to normoxia or SuHx for 5 weeks. The SuHx-treated mice were administrated adenoviral-null (Ad-N) or adenoviral-ACE2-S680L/K788R (Ad-R) intratracheally at the beginning of the experiments. B and C, Summarized data (mean±SEM) showing RVSP (B) and Fulton index, the ratio of the weight of right ventricle (RV) to the weight of the left ventricle (LV) and septum (S) (RV/[LV+S], C) in normoxic (Nor) ACE2-D and ACE2-L mice and SuHx-treated ACE2-D and ACE2-L mice receiving Ad-N or Ad-R. D, Histological images with H&E staining of pulmonary arteries (Left) and summarized data (mean±SEM, Right) showing the pulmonary arterial wall thickness from Nor+ACE2-D, Nor+ACE2-L, SuHx+ACE2-D+Ad-N, SuHx+ACE2-L+Ad-N, or SuHx+ACE2-L+Ad-R mice. Scale bar = 20 µm. E, Western blot analysis (Left) of peNOS S1176 or T494, eNOS, ACE2, and MDM2, along with summarized data (mean±SEM, Right) showing the expression levels of peNOS S1176, peNOS T494, ACE2, and MDM2, in lung tissues from SuHx+ ACE2-D+Ad-N, SuHx+ACE2-L+Ad-N, or SuHx+ACE2-L+Ad-R mice. F, Quantitative polymerase chain reaction analysis of END1, ANGPT1, PTGIS, and BMPR2 mRNA in lung tissues from Nor+ACE2-D, Nor+ACE2-L, SuHx+ACE2-D+Ad-N, SuHx+ACE2-L+Ad-N, or SuHx+ACE2-L+Ad-R mice. Data are mean±SEM (5–9 mice per group). Normally distributed data (B through D and F) were analyzed by 1-way ANOVA test between multiple groups. Nonnormally distributed data (E) were analyzed using the Kruskal-Wallis test between multiple groups. *P<0.05 versus Nor+ACE2-L; #P<0.05 versus SuHx+ACE2-L+Ad-N; *P<0.05 between SuHx+ACE2-D+Ad-N and SuHx+ACE2-L+Ad-N as indicated. ACE2 indicates angiotensin-converting enzyme 2; ANGPT1, angiopoietin 1; BMPR2, bone morphogenetic protein receptor II; END1, endothelin-1; eNOS, endothelial nitric oxide synthase; H&E, hematoxylin and eosin; MDM2, murine double minute 2; PTGIS, prostacyclin synthase; RVSP, right ventricular systolic pressure; and SuHx, SU5416/hypoxia.

HHS Vulnerability Disclosure